LEXINGTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. ( KLDO), a clinical-stage healthcare company with a chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health, today announced that management will participate in a fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference in New York City on Monday, September 9, 2019 at 1:40 p.m. ET.
A live audio webcast will be available through the Investors & Media section of Kaleido’s website at https://investors.kaleido.com/events-presentations. An archived replay will be accessible for 90 days following the event.
About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the microbiome organ to treat disease and improve human health. The Company has built a human-centric proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.
Contact
Amy Reilly
617-890-5721
[email protected]
